Journal of Gambling Studies

, Volume 19, Issue 1, pp 85–109 | Cite as

Advances in the Pharmacological Treatment of Pathological Gambling

  • Jon E. Grant
  • Suck Won Kim
  • Marc N. Potenza


In the present paper we discuss the current status of drug treatment for pathological gambling and the scientific rationales underlying the various pharmacological approaches. Specifically, we summarize the treatment study results of serotonin reuptake inhibitors, mood stabilizers, opioid antagonists, and atypical antipsychotics in pathological gambling. We also discuss dosage strategies, the duration of treatment, issues surrounding medication compliance, and approaches to treatment-refractory pathological gambling, such as pharmacological and behavioral augmentation.

pathological gambling impulse control psychopharmacology 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Albanese, M.J., Khantzian, E.J., Murphy, S.L., & Green, A.I. (1994). Decreased substance use in chronically psychotic patients treated with clozapine. American Journal of Psychiatry, 151, 780–781. [Letter].Google Scholar
  2. American Psychiatric Association Committee on Nomenclature and Statistics. (1980). Diagnostic and statistical manual of mental disorders (3rd Ed.). Washington, D.C.: American Psychiatric Association.Google Scholar
  3. American Psychiatric Association Committee on Nomenclature and Statistics. (1987). Diagnostic and statistical manual of mental disorders (3rd Ed.-Revised). Washington, D.C.: American Psychiatric Association.Google Scholar
  4. American Psychiatric Association Committee on Nomenclature and Statistics. (2000). Diagnostic and statistical manual of mental disorders (4th Ed.-Text Revision). Washington, D.C.: American Psychiatric Association.Google Scholar
  5. Barrett, R.P., Feinstein, C., & Hole, W.T. (1989). Effects of naloxone and naltrexone on self-injury: a double-blind, placebo-controlled analysis. American Journal of Mental Retardation, 93, 644–651.Google Scholar
  6. Blanco, C., Moreyra, P., Nunes, E.V., Sáiz-Ruiz, J., & Ibánez, A. (2001). Pathological gambling: addiction or compulsion? Seminars in Clinical Neuropsychiatry, 6, 167–176.Google Scholar
  7. Blanco, C., Orensanz-Munoz, L., Blanco-Jerez, C., & Saiz-Ruiz, J. (1996). Pathological gambling and platelet MAO activity: a psychobiological study. American Journal of Psychiatry, 153, 119–121.Google Scholar
  8. Blanco, C., Petkova, E., Ibanez, A., & Sáiz-Ruiz, J. (2002). A pilot placebo-controlled study of fluvoxamine for pathological gambling. Annals of Clinical Psychiatry, 14, 9–15.Google Scholar
  9. Broekkamp, C.L. & Phillips, A.G. (1979). Facilitation of self-stimulation behavior following intracerebral microinjections of opioids into the ventral tegmental area. Pharmacology Biochemistry and Behavior, 11, 289–295.Google Scholar
  10. Buckley, P., Thompson, P., Way, L., & Meltzer, H.Y. (1994). Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy. American Journal of Psychiatry, 151, 385–389.Google Scholar
  11. Carrasco, J.L., Saiz-Ruiz, J., Hollander, E., Cesar, J., & Lopez-Ibor Jr., J.J. (1994). Low platelet monoamine oxidase activity in pathological gambling. Acta Psychiatrica Scandinavia, 90, 427–3Google Scholar
  12. Carroll, K.M., Ball, S.A., Nich, C., O'Connor, P.G., Eagan, D.A., Frankforter, T.L., Triffleman, E.G., Shi, J., & Rounsaville, B.J. (2001). Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence. Archives of General Psychiatry, 58, 755–761.Google Scholar
  13. Chambers, R.A., Krystal, J. H., & Self, D.W. (2001). A neurobiological basis for substance abuse comorbidity in schizophrenia. Biological Psychiatry, 50, 71–83.Google Scholar
  14. Chambers, R.A. & Potenza, M.N. (2001). Schizophrenia and pathological gambling. American Journal of Psychiatry, 158, 497–498. [Letter].Google Scholar
  15. Chambers, R.A. & Potenza, M.N. (in press). Impulse control disorders. In M.J. Adinoff & R.B. Daroff (Eds.), The encyclopedia of neurological sciences. San Diego, California: Academic Press.Google Scholar
  16. Crockford, D.N. & el-Guebaly, N. (1998). Naltrexone in the treatment of pathological gambling and alcohol dependence. Canadian Journal of Psychiatry, 43, 86. [Letter].Google Scholar
  17. Cunningham-Williams, R.M. & Cottler, L.B. (2001). The epidemiology of pathological gambling. Seminars in Clinical Neuropsychiatry, 6:155–166.Google Scholar
  18. Cunningham-Williams, R.M., Cottler, L.B., Compton, W.M. 3rd, & Spitznagel, E.L. (1998). Taking chances: problem gamblers and mental health disorders—results from the St. Louis Epidemiologic Catchment Area Study. American Journal of Public Health. 88:1093–1096.Google Scholar
  19. Daly, K.A. & Fatemi, S.H. (1999). Lamotrogine and impulse behavior. Canadian Journal of Psychiatry, 44, 395-396. [Letter].Google Scholar
  20. Davidson, D., Swift, R.M., & Fitz, E. (1996). Naltrexone increases the latency to drink in social drinkers. Alcoholism and Clinical Experimental Research, 20, 732–739.Google Scholar
  21. DeCaria, C.M., Begaz, T., & Hollander, E. (1998). Serotonergic and noradrenergic function in pathological gambling. CNS Spectrums, 3, 38–47.Google Scholar
  22. DeCaria, C.M., Hollander, E., Grossman, R., Wong, C.M., Mosovich, S.A., & Cherkasky, S. (1996). Diagnosis, neurobiology, and treatment of pathological gambling. Journal of Clinical Psychiatry, 57(S8), 80–83.Google Scholar
  23. De la Gandara, J.J. (1999). Fluoxetine: open-trial in pathological gambling. Presented at the 152nd Annual Meeting of the American Psychiatric Association; May 16–21; Washington, DC. [Abstract].Google Scholar
  24. Farren, C.K., Rezvani, A.H., Overstreet, D., & O'Malley, S. (2000). Combination pharmacotherapy in alcoholism: a novel treatment approach. CNS Spectrums, 5, 70–76.Google Scholar
  25. Feeney, D.J. & Klykylo, W.M. (1997). Treatment for kleptomania. Journal of the American Academy of Child & Adolescent Psychiatry, 36, 723–724.Google Scholar
  26. Gardell, L.R., Reid, L.D., Boedeker, K.L., Liakos, T.M., & Hubbell, C.L. (1997a). Isradipine and naltrexone in combination with isradipine interact with a period of abstinence to reduce rats' intakes of an alcoholic beverage. Alcoholism and Clinical Experimental Research, 21, 1592–1598.Google Scholar
  27. Gardell, L.R., Whalen, C.A., Chattophadyay, S., Cavallaro, C.A., Hubbell, C.L., & Reid, L.D. (1997b). Combination of naltrexone and fluoxetine on rats' propensity to take alcoholic beverage. Alcoholism and Clinical Experimental Research, 21, 1435–1439.Google Scholar
  28. George, T.P. & Krystal, J.H. (2000). Comorbidity of psychiatric and substance abuse disorders. Current Opinion in Psychiatry, 13, 327–331.Google Scholar
  29. George, T.P., Ziedonis, D.M., Feingold, A., Pepper, W.T., Satterburg, C.A., Winkel, J., Rounsaville, B. J., & Kosten, T.R. (2000). Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. American Journal of Psychiatry, 157, 1835–1842.Google Scholar
  30. Gerstein, D., Hoffmann, J., Larison, C., Engelman, L., Murphy, S., Palmer, A., Chuchro, L., Toce, M., Johnson, R., Buie, T., & Hill, M.A. (1999). Gambling impact and behavior study. National Opinion Research Center, University of Chicago.".Google Scholar
  31. Goodman, W.K., McDougle, C.J., Price, L.H., Riddle, M.A., Pauls, D.L., & Leckman, J.F. (1990). Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive-compulsive disorder? Journal of Clinical Psychiatry, 51, 36–43.Google Scholar
  32. Goodwin, F.K. & Jamison, K.R. (1990). Manic-depressive illness. New York City, NY: Oxford University Press.Google Scholar
  33. Grant, J.E. & Kim, S.W. (2001a). Demographic and clinical features of 131 adult pathological gamblers. Journal of Clinical Psychiatry, 62, 957–962.Google Scholar
  34. Grant, J.E. & Kim, S.W. (2001b). Pharmacotherapy of pathological gambling disorder. Psychiatric Annals, 32, 161–170.Google Scholar
  35. Grant, J.E. & Kim, S.W. (2002). An open label study of naltrexone in the treatment of kleptomania. Journal of Clinical Psychiatry, 63, 349–356.Google Scholar
  36. Guy, W. (1976). ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education and Welfare publication (ADM) 76–338. Rockville, MD: National Institute of Mental Health, 218–222.Google Scholar
  37. Haller, R. & Hinterhuber, H. (1994). Treatment of pathological gambling with carbamazepine. Pharmacopsychiatry, 27, 129.Google Scholar
  38. Head, C.A., Vessichio, J.C., Sahady, D.M., Kosten, T.R., & George, T. P. (2000). Buproprion versus placebo for smoking cessation in schizophrenia: effects of atypical antipsychotic drugs. Presented at the 7 th Annual Meeting of the Society for Research of Nicotine and Tobacco. [Abstract].Google Scholar
  39. Hollander, E. (2001). “Very bad behaviors” in the Symposium “The impulsive aggressive spectrum: Challenging populations.” Presented at the 154th Annual Meeting of the American Psychiatric Association; May 7 and 8; New Orleans, LA. [Abstract].Google Scholar
  40. Hollander, E., DeCaria, C.M., Finkell, J.N., Begaz, T., Wong, C.M., & Cartwright, C. (2000). A randomized double-blind fluvoxamine/placebo crossover trial in pathological gambling. Biological Psychiatry, 47, 813–817.Google Scholar
  41. Hollander, E., DeCaria, C.M., Mari, E., Wong, C.M., Mosovich, S., Grossman, R., & Begaz, T. (1998). Short-term single-blind fluvoxamine treatment of pathological gambling. American Journal of Psychiatry, 155, 1781–1783.Google Scholar
  42. Hollander, E., Frenkel, M., DeCaria, C., Trungold, S., & Stein, D.J. (1992). Treatment of pathological gambling with clomipramine. American Journal of Psychiatry, 149, 710–711. [Letter].Google Scholar
  43. Hollander, E. & Wong, C.M. (1995). Obsessive-compulsive spectrum disorders. Journal of Clinical Psychiatry, 56(S4), 3–6.Google Scholar
  44. Hollister, L., Schwin, R.L., & Kasper, P. (1977). Naltrexone treatment of opiate-dependent persons. Drug and Alcohol Dependence, 2, 203–209.Google Scholar
  45. Holmes, E.K., Mateczun, J.M., Lall, R., Wilcove, G.L. (1998). Pilot study of suicide risk factors among personnel in the United States Marine Corps (Pacific Forces). Psychological Reports, 83, 3–11.Google Scholar
  46. Jaffe, A.J., Rounsaville, B., Chang, G., Shottenfeld, R.S., Meyer, R.E., & O'Malley, S.S. (1996). Naltrexone, relapse prevention and supportive therapy with alcoholics: an analysis of patient matching. Journal of Consulting Clinical Psychology, 64, 1044–1053.Google Scholar
  47. Kane, J., Honigfeld, G., Singer, J, & Meltzer, H. (1988). Clozapine for the treatment-resistant schizophrenic: a double blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789–796.Google Scholar
  48. Kapur, S. (1998). A new framework for investigating antipsychotic action in humans: lessons from PET imaging. Molecular Psychiatry, 3, 135–140.Google Scholar
  49. Kim, S.W. (1998). Opioid antagonists in the treatment of impulse control disorders. Journal of Clinical Psychiatry, 59, 159–164.Google Scholar
  50. Kim, S.W. & Grant, J.E. (2001a). An open naltrexone treatment study of pathological gambling disorder. International Clinical Psychopharmacology, 16, 285–289.Google Scholar
  51. Kim, S.W. & Grant, J.E. (2001b). The psychopharmacology of pathological gambling. Seminars in Clinical Neuropsychiatry, 6, 184–194.Google Scholar
  52. Kim, S.W. & Grant, J.E. (2001c). Personality dimensions in pathological gambling disorder and obsessive compulsive disorder. Psychiatry Research, 104, 205–212.Google Scholar
  53. Kim, S.W., Grant, J.E., Adson, D.E., & Remmel, R.P. (2001a). A preliminary report on a possible naltrexone and nonsteroidal analgesics interaction. Journal of Clinical Psychopharmacology, 21, 632–634. [Letter].Google Scholar
  54. Kim, S.W., Grant, J.E., Adson, D.E., & Shin, Y.C. (2001b). Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biological Psychiatry, 49, 914–921.Google Scholar
  55. Kim, S.W., Grant, J.E., Adson, D.E., Shin, Y.C., & Zaninelli, R.M. (2002). A double-blind, placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. Journal of Clinical Psychiatry, 63, 501–507.Google Scholar
  56. Ladouceur, R., Boisvert, J.M., & Dumont, J. (1994). Cognitive-behavioral treatment for adolescent pathological gamblers. Behavior Modification, 18, 230–242.Google Scholar
  57. Lesieur, H.R. & Rosenthal, R.J. (1991). Pathological gambling: a review of the literature (prepared for the American Psychiatric Association Task Force of DSM-IV Committee on Disorders of Impulse Control Not Elsewhere Classified). Journal of Gambling Studies, 7, 5–39.Google Scholar
  58. Mason, B.J. & Ownby, R.L. (2000). Acamprosate for the treatment of alcohol dependence: a review of double-blind, placebo-controlled trials. CNS Spectrums, 5, 58–69.Google Scholar
  59. Martin, A., Scahill, L., Vitulano, L., & King, R.A. (1998). Stimulant use and trichotillomania. Journal of the American Academy of Child & Adolescent Psychiatry, 37, 349–50.Google Scholar
  60. Matthews, R.T. & German, D.C. (1984). Electrophysiological evidence for excitation of rat ventral tegmental area dopamine neurons by morphine. Neuroscience, 11, 617–625.Google Scholar
  61. McDougle, C.J., Epperson, C.N., Pelton, G.H., Wasylink, S., & Price, L.H. (2000). A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Archives of General Psychiatry, 57, 794–801.Google Scholar
  62. McDougle, C.J., Goodman, W.K., Leckman, J.F., Lee, N.C., Heninger, G.R., & Price, L.H. (1994). Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics. Archives of General Psychiatry, 51, 302–308.Google Scholar
  63. McElroy, S.L., Hudson, J.I., Phillips, K.A., Keck, P.E., & Pope, H.G. (1993). Clinical and theoretical implications of a possible link between obsessive-compulsive and impulse control disorders. Depression, 1, 121–132.Google Scholar
  64. McElroy, S.L., Pope, H.G. Jr., Keck, P.E., Hudson, J.I., Phillips, K.A., & Strakowski, S.M. (1996). Are impulse-control disorders related to bipolar disorder? Comprehensive Psychiatry, 37, 229–240.Google Scholar
  65. McLellan, A.T., Arndt, I.O., Metzger, D.S., Woody, G.E., & O'Brien, C.P. (1993). The effects of psychosocial services in substance abuse treatment. Journal of the American Medical Association, 269, 1953–1959.Google Scholar
  66. Meltzer, H. Y. (1995). Atypical antipsychotic drugs. In F.E. Bloom & D.J. Kupfer (Eds), Neuropsychopharmacology: the fourth generation of progress. New York: D.J. Raven Press.Google Scholar
  67. Meltzer, H. Y. (1999). The role of serotonin in antipsychotic drug action. Neuropsychopharmacology, 21, 106S–115S.Google Scholar
  68. Mitchell, J.E., Morley, J.E., Levine, A.S., Hatsukami, D., Gannon, M., & Pfohl, D. (1987). High-dose naltrexone therapy and dietary counseling for obesity. Biological Psychiatry, 22, 35–42.Google Scholar
  69. Monti, P.M, Rohsenow, D.J., Hutchison, K., Swift, R.M., Mueller, T.I., Colby, S.M., Brown, R.A., Gulliver, S.B., Gordon, A., & Abrams, D.B. (1999). Naltrexone's effect on cue-elicited craving among alcoholics in treatment. Alcoholism and Clinical Experimental Research, 23, 1386–1394.Google Scholar
  70. Monti, P.M, Rohsenow, D.J., Swift, R.M., Abrams, D.B., Colby, S.M., & Mueller, T.I. (1996). Effect of naltrexone on urge to drink during alcohol cue exposure: preliminary results. Alcoholism and Clinical Experimental Research, 20, 92A.Google Scholar
  71. Moskowitz, J.A. (1980). Lithium and lady luck: use of lithium carbonate in compulsive gambling. New York State Journal of Medicine, 80, 785–788.Google Scholar
  72. Nordin, C. & Eklundh, T. (1999). Altered CSF 5-HIAA disposition in pathologic male gamblers. CNS Spectrums, 4, 25–33.Google Scholar
  73. O'Brien, C.P. (1997). A range of research-based pharmacotherapies for addiction. Science, 278, 66–70.Google Scholar
  74. O'Malley, S.S., Jaffe, A.J., Chang, G., Schottenfeld, R.S., Meyer, R.E., & Rounsaville, B.J. (1992). Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Archives of General Psychiatry, 49, 881–887.Google Scholar
  75. Pallanti, S., Quercioli, L., Sood, E., & Hollander E. (2002). Lithium and valproate treatment of pathological gambling: a randomized single-blind study. Journal of Clinical Psychiatry, 63, 559–564.Google Scholar
  76. Petry, N.M. & Armentano, C. (1999). Prevalence, assessment, and treatment of pathological gambling: a review. Psychiatric Services, 50, 1021–1027.Google Scholar
  77. Petry, N.M. & Roll, J.M. (2001). A behavioral approach to understanding and treating pathological gambling. Seminars in Clinical Neuropsychiatry, 6, 177–183.Google Scholar
  78. Phillips, A.G. & LePiane, F.G. (1980). Reinforcing effects of morphine microinjection onto the ventral tegmental area. Pharmacology Biochemistry and Behavior, 12, 965–968.Google Scholar
  79. Phillips, D.P., Welty, W.R., & Smith, M.M. (1997). Elevated suicide levels associated with legalized gambling. Suicide and Life Threatening Behavior, 27, 373–378.Google Scholar
  80. Physicians' Desk Reference (2001). 55th Ed. Medical Economics Company. Montvale, NJ.Google Scholar
  81. Potenza, M.N. (2001). The neurobiology of pathological gambling. Seminars in Clinical Neuropsychiatry, 6, 217–226.Google Scholar
  82. Potenza, M.N. (2002). A perspective on future directions in the prevention, treatment and research of pathological gambling. Psychiatric Annals, 32, 203–207.Google Scholar
  83. Potenza, M.N., Fiellin, D.A., Heninger, G.R., Rounsaville, B.J., & Mazure, C.M. (2002). Gambling: an addictive behavior with primary care implications. Journal of General Internal Medicine, 17, 1–12.Google Scholar
  84. Potenza, M.N. & Hollander, E. (2002). Pathological gambling and impulse control disorders. In J. Coyle, C. Nemeroff, D. Charney, & K. Davis (Eds), Neuropsychopharmacology: the 5th generation of progress (pp. 1725–1741). Baltimore, MD: Lippincott Williams and Wilkens.Google Scholar
  85. Potenza, M.N., Kosten, T.R., & Rounsaville, B.J. (2001). Pathological gambling. Journal of the American Medical Association, 286, 141–144.Google Scholar
  86. Potenza, M.N. & McDougle, C.J. (1998). Potential of atypical antipsychotics in the treatment of non-psychotic disorders. CNS Drugs, 9, 213–232.Google Scholar
  87. Potenza, M.N., Steinberg, M.A., McLaughlin, S.D., Wu, R., Rounsaville, B.J., & O'Malley, S.S. (2000). Illegal behaviors in problem gambling: analysis of data from a gambling helpline. Journal of the American Academy of Psychiatry and the Law, 28, 389–403.Google Scholar
  88. Roth, A.S., Ostroff, R.B., & Hoffman, R.E. (1996). Naltrexone as a treatment for repetitive self-injurious behaviour: an open-label trial. Journal of Clinical Psychiatry, 57, 233–237.Google Scholar
  89. Rounsaville, B.J. (1995). Can psychotherapy rescue naltrexone treatment of opioid addiction? In L.S. Onken & J.D. Blaine (Eds.), Potentiating the effects of medications. Rockville, Maryland: National Institute on Drug Abuse Research Monograph, 105, 37–52.Google Scholar
  90. Rugle, L. (2000). The use of olanzapine in the treatment of video poker pathological gamblers. Presented at the conference entitled, “The Comorbidity of Pathological Gambling: A Current Research Synthesis” December 3–5; Las Vegas, Nevada. [Abstract].Google Scholar
  91. Saxena, S., Wang, D., Bystritsky, A., & Baxter, L.R. (1996). Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. Journal of Clinical Psychiatry, 57, 303–306.Google Scholar
  92. Seeman, P. (1992). Dopamine receptor sequences: therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology, 7, 261–284.Google Scholar
  93. Shaffer, H.J. & Hall, M.N. (1996). Estimating the prevalence of adolescent gambling disorders: a quantitative synthesis and guide toward standard gambling nomenclature. Journal of Gambling Studies, 12, 193–214.Google Scholar
  94. Shaffer, H.J., Hall, M.N., & Vander Bilt, J. (1999). Estimating the prevalence of disordered gambling behavior in the United States and Canada: a research synthesis. American Journal of Public Health, 89, 1369–1376.Google Scholar
  95. Shinohara, K., Yanagisawa, A., Kagota, Y., Gomi, A., Nemoto, K., Moriya, E., Furusawa, E., Furuya, K., & Tersawa, K. (1999). Physiological changes in Pachinko players; beta-endorphin, catecholamines, immune system substances and heart rate. Applied Human Science, 18, 37–42.Google Scholar
  96. Stein, D.J., Bouwer, M.B., Hawkridge, S., & Emsley, R.A. (1997). Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. Journal of Clinical Psychiatry, 58, 119–122.Google Scholar
  97. Stewart, J. (1984). Reinstatement of heroin and cocaine self-administration behavior in the rat by intracerebral application of morphine in the ventral tegmental area. Pharmacology Biochemistry and Behavior, 20, 917–923.Google Scholar
  98. Sutherland, G., Stapleton, J.A., Russell, M.A.H., & Feyerabend, C. (1995). Naltrexone, smoking behaviour and cigarette withdrawal. Psychopharmacology, 120, 418–425.Google Scholar
  99. Swift, R.M. (2000). Opioid antagonists and alcoholism treatment. CNS Spectrums, 5, 49–57.Google Scholar
  100. Sylvain, C., Ladouceur, R., & Boisvert, J.M. (1997). Cognitive and behavioral treatment of pathological gambling: a controlled study. Journal of Consulting and Clinical Psychology, 65, 727–732.Google Scholar
  101. van Wolfswinkel, L. & van Ree, J.M. (1985). Effects of morphine and naloxone on thresholds of ventral tegmental electrical self-stimulation. Naunyn-Schmiedebergs Archives of Pharmacology, 330, 84–92.Google Scholar
  102. Verebey, K.G. & Mule, S.J. (1985). Naltrexone (Trexan): a review of hepatotoxicity issues. NIDA Research Monograph, 67, 73–81.Google Scholar
  103. Volkow, N.D., & Fowler, J.S. (2000). Addiction, a disease of compulsion and drive: Involvement of the orbitofrontal cortex. Cerebral Cortex, 10, 318–325.Google Scholar
  104. Volpicelli, J.R., Alterman, A.I., Hayashida, M., & O'Brien, C.P. (1992). Naltrexone in the treatment of alcohol dependence. Archives of General Psychiatry, 49, 876–880.Google Scholar
  105. Volpicelli, J.R., Rhines, K.C., Rhines, J.S., Volpicelli, L.A., Alterman, A.I., & O'Brien, C.P. (1997). Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry, 54, 737–742.Google Scholar
  106. Walters, A.S., Barrett, R.P., Feinstein, C., Mercurio, A., & Hole, W.T. (1990). A case report of naltrexone treatment of self-injury and social withdrawal in autism. Journal of Autism and Developmental Disorders, 20, 169–176.Google Scholar
  107. Zimmerman, M. & Breen, R. (2002). An open-label study of citalopram in the treatment of pathological gambling. Journal of Clinical Psychiatry, 63, 44–48.Google Scholar

Copyright information

© Human Sciences Press, Inc. 2003

Authors and Affiliations

  • Jon E. Grant
    • 1
  • Suck Won Kim
    • 2
  • Marc N. Potenza
    • 3
  1. 1.Department of PsychiatryUniversity of Minnesota School of MedicineMinneapolis
  2. 2.University of MinnesotaUSA
  3. 3.Yale UniversityUSA

Personalised recommendations